Division of Neuroscience, IRCCS Scientific Institute Ospedale San Raffaele.
University Vita-Salute San Raffaele, Milano, Italy.
Int Clin Psychopharmacol. 2022 May 1;37(3):79-81. doi: 10.1097/YIC.0000000000000403.
Raised inflammatory setpoints have been associated with major depression and its detrimental consequences on brain function, as they lead to increased production of cytokines, changes in gene expression and activated brain microglia. Three main lines of evidence support immune-inflammatory mechanisms as targets for the treatment of depression. First, higher inflammation hampers response to antidepressants, and effective antidepressant treatment decreases inflammation. Second, conventional antidepressants share immune-modulatory and anti-inflammatory properties, which could affect inflammation during the depression. Third, anti-inflammatory and immune-modulatory treatments proved superior to placebo in randomized controlled antidepressant trials. New targets and new pharmacologic treatment for immune-mediated inflammatory diseases have been identified and tested in several medical settings and interest is warranted for testing them as antidepressants.
炎症设定点升高与重度抑郁症及其对大脑功能的不利影响有关，因为它们会导致细胞因子产生增加、基因表达变化和激活脑小胶质细胞。有三条主要证据支持免疫炎症机制是治疗抑郁症的靶点。首先，更高的炎症会阻碍对抗抑郁药的反应，而有效的抗抑郁治疗会降低炎症。其次，传统的抗抑郁药具有免疫调节和抗炎特性，这可能会在抑郁症期间影响炎症。第三，抗炎和免疫调节治疗在随机对照抗抑郁试验中优于安慰剂。已经在多个医学领域中确定和测试了新的针对免疫介导的炎症性疾病的靶点和新的药物治疗方法，有理由对它们作为抗抑郁药进行测试。
